VKTX
- Viking Therapeutics, Inc.
()
Overview
Company Summary
Viking Therapeutics, Inc. is a biopharmaceutical company that specializes in the development of novel therapies for metabolic and endocrine disorders. The company primarily focuses on the research and development of drugs to address areas such as non-alcoholic steatohepatitis (NASH), obesity, and type 2 diabetes.
Viking Therapeutics is committed to utilizing its expertise in small molecule drug development to target specific cellular receptors involved in metabolic pathways. By targeting these receptors, the company aims to develop innovative therapeutics with the potential to improve patient outcomes and address unmet medical needs in the field of metabolic disorders.
One of Viking Therapeutics' key areas of focus is NASH, a progressive liver disease closely associated with obesity and type 2 diabetes. NASH has become a major global health concern due to its increasing prevalence and lack of approved treatments. Viking Therapeutics is actively developing a drug candidate called VK2809, which targets the thyroid hormone receptor beta.
In addition to NASH, Viking Therapeutics is also exploring the potential of its drug candidates in other metabolic disorders. For instance, VK0214, a selective thyroid hormone receptor beta agonist, is being studied for the treatment of X-linked adrenoleukodystrophy (X-ALD), a rare genetic disorder affecting the nervous system.
Overall, Viking Therapeutics is dedicated to advancing the understanding of metabolic disorders and developing cutting-edge therapies that have the potential to make a significant impact on patients' lives. Through its innovative drug development approach, the company strives to bring novel treatment options to market and improve the management of metabolic and endocrine conditions.